Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abbott LaboratoriesXSWX:ABT +9.59%80 EV-to-EBITDA is 17.08 as of Jul. 17, 2026, which is 15% below its 10-year median of 20.08. GuruFocus rates XSWX:ABT with a GF Score™ of 80/100 and a GF Value™ of CHF105.60. Among 511 Medical Devices & Instruments companies, Abbott Laboratories ranks worse than 58.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Abbott Laboratories's enterprise value is CHF161,472 Mil.
Abbott Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF9,456 Mil. Therefore, Abbott Laboratories's EV-to-EBITDA for today is 17.08.
The historical rank and industry rank for Abbott Laboratories's EV-to-EBITDA or its related term are showing as below:
XSWX:ABT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.22 Med: 20.08 Max: 29.25
Current: 16.86
During the past 13 years, the highest EV-to-EBITDA of Abbott Laboratories was 29.25. The lowest was 13.22. And the median was 20.08.
XSWX:ABT's EV-to-EBITDA is ranked worse than 58.12% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.29
vs XSWX:ABT: 16.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Abbott Laboratories's PE Ratio (TTM) for today is calculated as:
Abbott Laboratories's share price for today is CHF80.00.
Abbott Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2.854.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Abbott Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABT vs SYK, MDT, BSX: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Abbott Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's EV-to-EBITDA falls into.
Abbott Laboratories's current Enterprise Value is CHF161,472 Mil.
Abbott Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF9,456 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (XSWX:ABT) has a EV-to-EBITDA of 17.08 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abbott Laboratories. This is 15% below median its historical median of 20.08. Over the past decade, Abbott Laboratories' EV-to-EBITDA has ranged from 13.22 to 29.25. According to the industry distribution chart, Abbott Laboratories ranks #297 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 58.1%.
Is Abbott Laboratories' EV-to-EBITDA too high?
Abbott Laboratories' current EV-to-EBITDA of 17.08 is 15% below median its 10-year median of 20.08. Over the past 10 years, this metric has ranged from a low of 13.22 to a high of 29.25. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.29. Abbott Laboratories' value of 17.08 is 19.5% above this industry median. Based on the distribution chart, Abbott Laboratories ranks #297 out of 511 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' EV-to-EBITDA compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #297 out of 511 companies for EV-to-EBITDA. This places Abbott Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 14.29. Abbott Laboratories' value of 17.08 is 19.5% above this benchmark. Historically, Abbott Laboratories' own EV-to-EBITDA has ranged from 13.22 to 29.25 over the past decade. While the company's 10-year median is 20.08 vs. the industry median of 14.29, Abbott Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.29, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current EV-to-EBITDA of 17.08 is 19.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Abbott Laboratories. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current EV-to-EBITDA is 17.08, which is 15% below median its own 10-year median of 20.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Abbott Laboratories (XSWX:ABT) has a current EV-to-EBITDA of 17.08. The stock's GF Value™ is CHF105.60, compared to a current price of CHF80.00 — trading 24.2% below its estimated fair value. The current EV-to-EBITDA is 17.08, which is 15% below median its 10-year median of 20.08 and 19.5% above the Medical Devices & Instruments industry median of 14.29. Abbott Laboratories' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Abbott Laboratories (XSWX:ABT), the current EV-to-EBITDA is 17.08 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (XSWX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of CHF80.00 is trading 24.2% below its estimated GF Value™ of CHF105.60.
Key valuation signals for XSWX:ABT:
EV-to-EBITDA: 17.08 (15% below median its 10-year median of 20.08)
GF Value™: CHF105.60 vs. price of CHF80.00 (24.2% below fair value)
Industry Position: 19.5% above the Medical Devices & Instruments median (#297 of 511)
No single metric tells the full story. See the XSWX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
80GF Score
Get the complete analysis for XSWX:ABT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABT has been successfully added to your 
